46
Participants
Start Date
September 1, 2021
Primary Completion Date
August 30, 2024
Study Completion Date
June 30, 2028
Camrelizumab (anti-PD-1 inhibitor)
The patients will receive three cycles of Camrelizumab, with 14 days each. 200mg of Carrelizumab will be used intravenously on the first day of each cycle.
Apatinib (anti-VEGFR inhibitor)
The patients will receive Apatinib orally 250mg once a day from the first day of each cycle until the 9th day of the third cycle.
RECRUITING
Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai
Shanghai Jiao Tong University School of Medicine
OTHER